Shares of XOMA (XOMA) are active this morning, jumping +13.6% on heavy volume after a bullish article in Seeking Alpha said that with recent management changes the company is better positioned than anytime before to stage a comeback. In addition to new management, its key anti-inflammatory drug, Gevokizumab, is also in Phase III trials and looks very encouraging for wide array of applications.
From other sites
at CNBC.com (Mar 5, 2014)
at CNBC.com (Jan 10, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs